The neuropsychology of normal aging and preclinical Alzheimer's disease - PubMed (original) (raw)

The neuropsychology of normal aging and preclinical Alzheimer's disease

Richard J Caselli et al. Alzheimers Dement. 2014 Jan.

Abstract

Objective: A National Institute on Aging-sponsored work group on preclinical Alzheimer's disease (AD) articulated the need to characterize cognitive differences between normal aging and preclinical AD.

Methods: Seventy-one apolipoprotein E (APOE) ε4 homozygotes, 194 ε3/ε4 heterozygotes, and 356 ε4 noncarriers age 21 to 87 years who were cognitively healthy underwent neuropsychological testing every 2 years. Longitudinal trajectories of test scores were compared between APOE subgroups.

Results: There was a significant effect of age on all cognitive domains in both APOE ε4 carriers and noncarriers. A significant effect of APOE ε4 gene dose was confined to the memory domain and the Dementia Rating Scale. Cross-sectional comparisons did not discriminate the groups.

Conclusions: Although cognitive aging patterns are similar in APOE ε4 carriers and noncarriers, preclinical AD is characterized by a significant ε4 gene dose effect that impacts memory and is detectable longitudinally. Preclinical neuropsychological testing strategies should emphasize memory-sensitive measures and longitudinal design.

Keywords: Age-related memory loss; Apolipoprotein E; Cognitive aging; Longitudinal testing; Mild cognitive impairment; Preclinical Alzheimer's disease.

Copyright © 2014 The Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

PubMed Disclaimer

Figures

Figure one. Selective Reminding Test, Free Recall (Total)

There is accelerating decline with increasing age that exhibits a significant APOE e4 gene dose effect.

Similar articles

• Cognitive domain decline in healthy apolipoprotein E epsilon4 homozygotes before the diagnosis of mild cognitive impairment.
  Caselli RJ, Reiman EM, Locke DE, Hutton ML, Hentz JG, Hoffman-Snyder C, Woodruff BK, Alexander GE, Osborne D. Caselli RJ, et al. Arch Neurol. 2007 Sep;64(9):1306-11. doi: 10.1001/archneur.64.9.1306. Arch Neurol. 2007. PMID: 17846270
• Cerebrovascular risk factors and preclinical memory decline in healthy APOE ε4 homozygotes.
  Caselli RJ, Dueck AC, Locke DE, Sabbagh MN, Ahern GL, Rapcsak SZ, Baxter LC, Yaari R, Woodruff BK, Hoffman-Snyder C, Rademakers R, Findley S, Reiman EM. Caselli RJ, et al. Neurology. 2011 Mar 22;76(12):1078-84. doi: 10.1212/WNL.0b013e318211c3ae. Epub 2011 Feb 16. Neurology. 2011. PMID: 21325652 Free PMC article.
• APOE ε4, white matter hyperintensities, and cognition in Alzheimer and Lewy body dementia.
  Mirza SS, Saeed U, Knight J, Ramirez J, Stuss DT, Keith J, Nestor SM, Yu D, Swardfager W, Rogaeva E, St George Hyslop P, Black SE, Masellis M; Alzheimer's Disease Neuroimaging Initiative. Mirza SS, et al. Neurology. 2019 Nov 5;93(19):e1807-e1819. doi: 10.1212/WNL.0000000000008377. Epub 2019 Oct 1. Neurology. 2019. PMID: 31575706 Free PMC article.
• Alzheimer's disease genetic risk and cognitive reserve in relationship to long-term cognitive trajectories among cognitively normal individuals.
  Pettigrew C, Nazarovs J, Soldan A, Singh V, Wang J, Hohman T, Dumitrescu L, Libby J, Kunkle B, Gross AL, Johnson S, Lu Q, Engelman C, Masters CL, Maruff P, Laws SM, Morris JC, Hassenstab J, Cruchaga C, Resnick SM, Kitner-Triolo MH, An Y, Albert M. Pettigrew C, et al. Alzheimers Res Ther. 2023 Mar 28;15(1):66. doi: 10.1186/s13195-023-01206-9. Alzheimers Res Ther. 2023. PMID: 36978190 Free PMC article.

Cited by

• APOE ε4 influences cognitive decline positively in APP and negatively in PSEN1 mutation carriers with autosomal-dominant Alzheimer's disease.
  Almkvist O, Johansson C, Laffita-Mesa J, Thordardottir S, Graff C. Almkvist O, et al. Eur J Neurol. 2022 Dec;29(12):3580-3589. doi: 10.1111/ene.15536. Epub 2022 Sep 11. Eur J Neurol. 2022. PMID: 36039401 Free PMC article.
• Subtle changes in daily functioning predict conversion from normal to mild cognitive impairment or dementia: an analysis of the NACC database.
  Nowrangi MA, Rosenberg PB, Leoutsakos JS. Nowrangi MA, et al. Int Psychogeriatr. 2016 Dec;28(12):2009-2018. doi: 10.1017/S1041610216000995. Epub 2016 Aug 8. Int Psychogeriatr. 2016. PMID: 27585497 Free PMC article.
• Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals.
  Qin T, Prins S, Groeneveld GJ, Van Westen G, de Vries HE, Wong YC, Bischoff LJM, de Lange ECM. Qin T, et al. Int J Mol Sci. 2020 Apr 30;21(9):3158. doi: 10.3390/ijms21093158. Int J Mol Sci. 2020. PMID: 32365768 Free PMC article. Review.
• Verbal memory formation across PET-based Braak stages of tau accumulation in Alzheimer's disease.
  Fernández Arias J, Therriault J, Thomas E, Lussier FZ, Bezgin G, Tissot C, Servaes S, Mathotaarachchi SS, Schoemaker D, Stevenson J, Rahmouni N, Kang MS, Pallen V, Poltronetti NM, Wang YT, Kunach P, Chamoun M, Quispialaya S KM, Vitali P, Massarweh G, Gauthier S, Rajah MN, Pascoal T, Rosa-Neto P. Fernández Arias J, et al. Brain Commun. 2023 May 18;5(3):fcad146. doi: 10.1093/braincomms/fcad146. eCollection 2023. Brain Commun. 2023. PMID: 37252014 Free PMC article.
• Classifying Parkinson's Disease Patients With Syntactic and Socio-emotional Verbal Measures.
  Baez S, Herrera E, Trujillo C, Cardona JF, Diazgranados JA, Pino M, Santamaría-García H, Ibáñez A, García AM. Baez S, et al. Front Aging Neurosci. 2020 Nov 23;12:586233. doi: 10.3389/fnagi.2020.586233. eCollection 2020. Front Aging Neurosci. 2020. PMID: 33328964 Free PMC article.

References

1. 1. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alz Dem. 2011;7:280–292. - PMC - PubMed
2. 1. Saunders AM, Strittmatter WJ, Schmechel D, George-Hyslop PH, Pericak-Vance MA, Joo SH, et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology. 1993;43:1467–1472. - PubMed
3. 1. Caselli RJ, Dueck AC, Osborne D, Sabbagh MN, Connor DJ, Ahern GL, et al. Longitudinal modeling of age-related memory decline and the APOE epsilon4 effect. N Engl J Med. 2009;361:255–263. - PMC - PubMed
4. 1. Howieson DB, Carlson NE, Moore MM, Wasserman D, Abendroth CD, Payne-Murphy J, Kaye JA. Trajectory of mild cognitive impairment onset. J Int Neuropsychol Soc. 2008;14:192–198. - PubMed
5. 1. Bouras C, Hof PR, Giannakopoulos P, Michel JP, Morrison JH. Regional distribution of neurofibrillary tangles and senile plaques in the cerebral cortex of elderly patients: a quantitative evaluation of a one-year autopsy population from a geriatric hospital. Cereb Cortex. 1994;4:138–150. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science
  • Europe PubMed Central
  • PubMed Central
  • Wiley

• Other Literature Sources

  • scite Smart Citations

• Medical

  • MedlinePlus Health Information

• Miscellaneous

  • NCI CPTAC Assay Portal